Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC) is a research paper published in Journal for ImmunoTherapy of Cancer (2022). On theSindex it has a DataRank of 1.2. It has been cited 52 times, with 40 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.596
From this paper's citation signal
Citation Network Contribution
0.580
From 35 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 40 citers.
National Cancer Institute
Grant: P30 CA014520
National Cancer Institute
Grant: R01 CA129154
Prostate Cancer Foundation
Grant: 2014 Movember-PCF Challenge Award
NCI NIH HHS
Grant: R01 CA219154
National Institutes of Health
Grant: 5P30CA014520-18
CANCER CENTER SUPPORT
Madison Vaccines Inc.
FWCI
3.40
Citation Percentile
0.9%
Influential Citations
1
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals